Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses.
Saved in:
| Title: | Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. |
|---|---|
| Authors: | Friedman CF; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA friedmac@mskcc.org.; Department of Medicine, Weill Cornell Medicine, New York, New York, USA., Spencer C; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA., Cabanski CR; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA., Panageas KS; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Wells DK; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA., Ribas A; Department of Medicine, University of California Los Angeles, Los Angeles, California, USA., Tawbi H; Department of Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Tsai K; Department of Medicine, University of California San Francisco, San Francisco, California, USA., Postow M; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Department of Medicine, Weill Cornell Medicine, New York, New York, USA., Shoushtari A; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Department of Medicine, Weill Cornell Medicine, New York, New York, USA., Chapman P; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Department of Medicine, Weill Cornell Medicine, New York, New York, USA., Karakunnel J; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA., Bucktrout S; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA., Gherardini P; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA., Hollmann TJ; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Chen RO; Personalis Inc, Menlo Park, California, USA., Callahan M; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Department of Medicine, Weill Cornell Medicine, New York, New York, USA., LaVallee T; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA., Ibrahim R; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA., Wolchok J; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Department of Medicine, Weill Cornell Medicine, New York, New York, USA. |
| Source: | Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Jan; Vol. 10 (1). |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 35074903 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Friedman+CF%22">Friedman CF</searchLink>; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA friedmac@mskcc.org.; Department of Medicine, Weill Cornell Medicine, New York, New York, USA.<br /><searchLink fieldCode="AU" term="%22Spencer+C%22">Spencer C</searchLink>; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Cabanski+CR%22">Cabanski CR</searchLink>; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Panageas+KS%22">Panageas KS</searchLink>; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.<br /><searchLink fieldCode="AU" term="%22Wells+DK%22">Wells DK</searchLink>; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Ribas+A%22">Ribas A</searchLink>; Department of Medicine, University of California Los Angeles, Los Angeles, California, USA.<br /><searchLink fieldCode="AU" term="%22Tawbi+H%22">Tawbi H</searchLink>; Department of Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Tsai+K%22">Tsai K</searchLink>; Department of Medicine, University of California San Francisco, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Postow+M%22">Postow M</searchLink>; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Department of Medicine, Weill Cornell Medicine, New York, New York, USA.<br /><searchLink fieldCode="AU" term="%22Shoushtari+A%22">Shoushtari A</searchLink>; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Department of Medicine, Weill Cornell Medicine, New York, New York, USA.<br /><searchLink fieldCode="AU" term="%22Chapman+P%22">Chapman P</searchLink>; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Department of Medicine, Weill Cornell Medicine, New York, New York, USA.<br /><searchLink fieldCode="AU" term="%22Karakunnel+J%22">Karakunnel J</searchLink>; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Bucktrout+S%22">Bucktrout S</searchLink>; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Gherardini+P%22">Gherardini P</searchLink>; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Hollmann+TJ%22">Hollmann TJ</searchLink>; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.<br /><searchLink fieldCode="AU" term="%22Chen+RO%22">Chen RO</searchLink>; Personalis Inc, Menlo Park, California, USA.<br /><searchLink fieldCode="AU" term="%22Callahan+M%22">Callahan M</searchLink>; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Department of Medicine, Weill Cornell Medicine, New York, New York, USA.<br /><searchLink fieldCode="AU" term="%22LaVallee+T%22">LaVallee T</searchLink>; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Ibrahim+R%22">Ibrahim R</searchLink>; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Wolchok+J%22">Wolchok J</searchLink>; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Department of Medicine, Weill Cornell Medicine, New York, New York, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101620585%22">Journal for immunotherapy of cancer</searchLink> [J Immunother Cancer] 2022 Jan; Vol. 10 (1). – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BMJ+Publishing+Group+Ltd%22">BMJ Publishing Group Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101620585 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2051-1426 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220511426%22">20511426 </searchLink><i>NLM ISO Abbreviation: </i>J Immunother Cancer <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35074903 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1136/jitc-2021-003853 Languages: – Code: eng Text: English Titles: – TitleFull: Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Friedman CF – PersonEntity: Name: NameFull: Spencer C – PersonEntity: Name: NameFull: Cabanski CR – PersonEntity: Name: NameFull: Panageas KS – PersonEntity: Name: NameFull: Wells DK – PersonEntity: Name: NameFull: Ribas A – PersonEntity: Name: NameFull: Tawbi H – PersonEntity: Name: NameFull: Tsai K – PersonEntity: Name: NameFull: Postow M – PersonEntity: Name: NameFull: Shoushtari A – PersonEntity: Name: NameFull: Chapman P – PersonEntity: Name: NameFull: Karakunnel J – PersonEntity: Name: NameFull: Bucktrout S – PersonEntity: Name: NameFull: Gherardini P – PersonEntity: Name: NameFull: Hollmann TJ – PersonEntity: Name: NameFull: Chen RO – PersonEntity: Name: NameFull: Callahan M – PersonEntity: Name: NameFull: LaVallee T – PersonEntity: Name: NameFull: Ibrahim R – PersonEntity: Name: NameFull: Wolchok J IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 01 Text: 2022 Jan Type: published Y: 2022 Identifiers: – Type: issn-electronic Value: 2051-1426 Numbering: – Type: volume Value: 10 – Type: issue Value: 1 Titles: – TitleFull: Journal for immunotherapy of cancer Type: main |
| ResultId | 1 |
